
    
      Patients will received Imatinib at a dose of 400mg daily. The tolerability of Imatinib given
      at a daily dose of 400mg will be assessed. The hematologic, cytogenetic and molecular
      responses will be evaluated at various check points.

      Donor/recipient chimerism during Imatinib therapy will be assessed. Survival will be
      estimated.
    
  